Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis
Neurology® Podcast
00:00
Drug Accelerator Approval
Anden, i realize that's challenging in and of itself for all of us has clinations. We either think this drug might be beneficial, we think this drug is not going to be beneficial. And it behooves us as clinitions to sort of put that baggage on the side lines and say, ok, here's why the fda gave this drug accelerator approval.
Transcript
Play full episode
